Afraxis 2.0 Inc, is a drug discovery company dedicated to developing computational approaches to issues in neuroscience. Afraxis has developed a central nervous system pharmaceutical screening technologies to approve of potential treatments for neurological and psychiatric disorders. The company has developed Enhanced Spine Platform (ESP), the technology analyzes the maturity of synaptic dendritic spines. The quantity of synaptic dendritic spines is crucial for the brain's ability to process information in the brain. Being able to analyze the quantity of dendritic spines is a predictor of whether a patient may have schizophrenia, Alzheimer's disease, Fragile X and other CNS disorders. The company's technology can also access the effectiveness of potential drugs and compounds relating to the central nervous system.
